Mersana Therapeutics (MRSN) Tops Q4 EPS by 5c

Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $9.1 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• BetterLife Pharma names Charles Duncan as director and audit chair
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook